Long-term Outcome of Adenosine A2A Receptor Antagonist on Lower Urinary Tract Symptoms in Male Parkinson Disease Patients

Kitta, Takeya; Yabe, Ichiro; Kanno, Yukiko; Higuchi, Madoka; Ouchi, Mifuka; Togo, Mio; Moriya, Kyoji; Takahashi, Ikuko; Matsushima, Masaaki; Sasaki, Hidenao; Shinohara, Nobuo

doi:10.1097/wnf.0000000000000281

Cited by 26 publications

(26 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a recent study concluded that in PD patients, consumption of 200 mg coffee a day for 6 months did not improve the motor symptoms. Still, other clinical studies using the A2A receptor antagonist, istradefylline, are encouraging given that istradefylline significantly improved motor manifestations of PD and reduced nighttime urinary frequency (Jankovic, 2008;Matsuura and Tomimoto, 2015;Kitta et al, 2018).…”

Section: Natural Products Green Tea and Coffee To Reduce The Risk Of mentioning

confidence: 99%

Strategies for the Treatment of Parkinson’s Disease: Beyond Dopamine

Iarkov

Barreto

Grizzell

et al. 2020

Front. Aging Neurosci.

View full text Add to dashboard Cite

Parkinson's disease (PD) is the second-leading cause of dementia and is characterized by a progressive loss of dopaminergic neurons in the substantia nigra alongside the presence of intraneuronal α-synuclein-positive inclusions. Therapies to date have been directed to the restoration of the dopaminergic system, and the prevention of dopaminergic neuronal cell death in the midbrain. This review discusses the physiological mechanisms involved in PD as well as new and prospective therapies for the disease. The current data suggest that prevention or early treatment of PD may be the most effective therapeutic strategy. New advances in the understanding of the underlying mechanisms of PD predict the development of more personalized and integral therapies in the years to come. Thus, the development of more reliable biomarkers at asymptomatic stages of the disease, and the use of genetic profiling of patients will surely permit a more effective treatment of PD.

show abstract

Section: Natural Products Green Tea and Coffee To Reduce The Risk Of mentioning

confidence: 99%

Strategies for the Treatment of Parkinson’s Disease: Beyond Dopamine

Iarkov

Barreto

Grizzell

et al. 2020

Front. Aging Neurosci.

View full text Add to dashboard Cite

show abstract

“…The first was prospective before‐after, the second was prospective non‐blinded clinical trial and the third was randomized clinical trial. The prospective before‐after studies by Brusa, Kitta, and Gubbiotti were in the field of medications. Crescenze and Brandi in a single prospective before‐after study evaluated the effect of SNM and parasacral electrostimulation, respectively.…”

Section: Resultsmentioning

confidence: 99%

Management of neurogenic bladder in patients with Parkinson's disease: A systematic review

Hajebrahimi

Chapple

Pashazadeh

et al. 2018

Neurourology and Urodynamics

View full text Add to dashboard Cite

Aims:To assess the different treatment methods in management of neurogenic bladder (NGB) in patients with Parkinson's disease (PD). Methods: A systematic search was performed in Cochrane library, EMBASE, Proquest, Clinicaltrial.gov, WHO, Google Scholar, MEDLINE via PubMed, Ovid, ongoing trials registers, and conference proceedings in November 11, 2017. All randomized controlled trials (RCTs) or quasi-RCTs comparing any treatment method for management of NGB in patients with PD were included. The titles and abstracts of all identified studies were evaluated independently by two investigators. Once all of the potential related articles were retrieved, each author separately evaluated the full text of each article and the quality of the methodology of the selected studies using the Cochrane appraisal risk of bias checklist and then the data about the patient's outcomes was extracted. We registered the title in Joanna Briggs Institute (JBI) that is available in http://joannabriggs.org/research/registered_titles.aspx. Results: We included 41 RCTs or quasi-RCTs or three observational study with a total of 1063 patients that evaluated pharmacological, neurosurgical, botulinum toxin, electrical neuromodulation, and behavioral therapy effects on NGB. Among the included studies only solifenacin succinate double-blind, randomized, placebocontrolled study was assessed as low risk of bias, and treatment led to an improvement in urinary incontinence. Conclusions: Although several interventions are available for treatment NGB in patients with PD, at present there is little or no evidence that treatment improves patient outcomes in this population. Additional large, well designed, randomized studies with improved methodology and reporting focused on patient-centered outcomes are needed.

show abstract

“…However, a larger-sized, placebo-controlled randomized study will need to be undertaken in order to confirm these results. Furthermore, our group also recently reported that significant improvements were observed during a 1-year istradefylline treatment of LUTS in PD patients [ 60 ]. Moreover, istradefylline may not only improve motor symptoms, but also LUTS in PD patients.…”

Section: Rodentsmentioning

confidence: 98%

Animal Model for Lower Urinary Tract Dysfunction in Parkinson’s Disease

Kitta

Ouchi

Chiba

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

Although Parkinson’s disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra and subsequent motor symptoms, various non-motor symptoms often precede these other symptoms. While motor symptoms are certainly burdensome, a wide range of non-motor symptoms have emerged as the key determinant of the quality of life in PD patients. The prevalence of lower urinary tract symptoms differs according to the study, with ranges between 27% and 63.9%. These can be influenced by the stage of disease, the presence of lower urinary tract-related comorbidities, and parallels with other manifestations of autonomic dysfunction. Animal models can provide a platform for investigating the mechanisms of PD-related dysfunction and for the assessment of novel treatment strategies. Animal research efforts have been primarily focused on PD motor signs and symptoms. However, the etiology of lower urinary tract dysfunction in PD has yet to be definitively clarified. Several animal PD models are available, each of which has a different effect on the autonomic nervous system. In this article, we review the various lower urinary tract dysfunction animal PD models. We additionally discuss techniques for determining the appropriate model for evaluating the development of lower urinary tract dysfunction treatments.

show abstract

Long-term Outcome of Adenosine A2A Receptor Antagonist on Lower Urinary Tract Symptoms in Male Parkinson Disease Patients

Abstract: Supplemental digital content is available in the text.

Cited by 26 publications

References 22 publications

Strategies for the Treatment of Parkinson’s Disease: Beyond Dopamine

Strategies for the Treatment of Parkinson’s Disease: Beyond Dopamine

Management of neurogenic bladder in patients with Parkinson's disease: A systematic review

Animal Model for Lower Urinary Tract Dysfunction in Parkinson’s Disease

Contact Info

Product

Resources

About